Open AccessThis article is
- freely available
Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization
Illumina Inc., San Diego, CA 92122, USA
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Department of Ophthalmology, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Singapore Eye Research Institute, Singapore National Eye Centre, 168751, Singapore
Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, 119074, Singapore
Departments of Pathology and Laboratory Medicine, Pediatrics and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Department of Pediatrics and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 15 January 2013 / Accepted: 22 February 2013 / Published: 5 March 2013
Abstract: Rapid progress in genomics and nanotechnology continue to advance our approach to patient care, from diagnosis and prognosis, to targeting and personalization of therapeutics. However, the clinical application of molecular diagnostics in ophthalmology has been limited even though there have been demonstrations of disease risk and pharmacogenetic associations. There is a high clinical need for therapeutic personalization and dosage optimization in ophthalmology and may be the focus of individualized medicine in this specialty. In several retinal conditions, such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and pre-threshold retinopathy of prematurity, anti-vascular endothelial growth factor therapeutics have resulted in enhanced outcomes. In glaucoma, recent advances in cytoskeletal agents and prostaglandin molecules that affect outflow and remodel the trabecular meshwork have demonstrated improved intraocular pressure control. Application of recent developments in nanoemulsion and polymeric micelle for targeted delivery and drug release are models of dosage optimization, increasing efficacy and improving outcomes in these major eye diseases.
Keywords: personalized medicine; pharmacogenetics; clinical utility; ophthalmology; VEGF; age-related macular degeneration; glaucoma; retinopathy; drug delivery; nanotechnology
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Ong, F.S.; Kuo, J.Z.; Wu, W.-C.; Cheng, C.-Y.; Blackwell, W.-L.B.; Taylor, B.L.; Grody, W.W.; Rotter, J.I.; Lai, C.-C.; Wong, T.Y. Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. J. Pers. Med. 2013, 3, 40-69.
Ong FS, Kuo JZ, Wu W-C, Cheng C-Y, Blackwell W-LB, Taylor BL, Grody WW, Rotter JI, Lai C-C, Wong TY. Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. Journal of Personalized Medicine. 2013; 3(1):40-69.
Ong, Frank S.; Kuo, Jane Z.; Wu, Wei-Chi; Cheng, Ching-Yu; Blackwell, Wendell-Lamar B.; Taylor, Brian L.; Grody, Wayne W.; Rotter, Jerome I.; Lai, Chi-Chun; Wong, Tien Y. 2013. "Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization." J. Pers. Med. 3, no. 1: 40-69.